Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

Core Insights - Genentech, a member of the Roche Group, announced that its investigational BTK inhibitor fenebrutinib met the primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with primary progressive multiple sclerosis [1] Group 1 - The Phase III FENtrepid study demonstrated a 12% reduction in the risk of disability progression with fenebrutinib compared to Ocrevus [1]